Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event

  • Brown, Adam (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date1/03/26 → 30/09/31

Clinical Trial Phase

  • Phase III (a & b)
  • External Sponsor